BR9913190A - Modulação de proteìnas quinase de linhagemmúltipla - Google Patents

Modulação de proteìnas quinase de linhagemmúltipla

Info

Publication number
BR9913190A
BR9913190A BR9913190-0A BR9913190A BR9913190A BR 9913190 A BR9913190 A BR 9913190A BR 9913190 A BR9913190 A BR 9913190A BR 9913190 A BR9913190 A BR 9913190A
Authority
BR
Brazil
Prior art keywords
protein kinase
methods
compound
modulation
activity
Prior art date
Application number
BR9913190-0A
Other languages
English (en)
Inventor
Anna Maroney
Craig A Dionne
Ernest Knight
Kevin M Walton
Nicola Neff
Marcie A Glicksman
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of BR9913190A publication Critical patent/BR9913190A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)

Abstract

"MODULAçãO DE PROTEìNAS QUINASE DE LINHAGEMMúLTIPLA". São providenciados métodos para identificarcompostos, que modulam a atividade de uma proteína quinase delinhagem múltipla e promovem a sobrevivência da célula ou morteda célula, compreendendo as etapas de contatar a célulacontendo a proteína quinase de linhagem múltipla com ocomposto, determinar, se o composto diminui a atividade daproteína quinase de linhagem múltipla, e determinar, se o compostopromove a sobrevivência da célula. Também são providenciadosmétodos para identificar compostos que podem ser de utilidade notratamento de distúrbios neurodegenerativos, e/ou inflamação.Também se providencia métodos para modulação da atividade deuma proteína quinase de linhagem múltipla compreendendo ocontato da proteína ou uma célula contendo a proteína com umcomposto indeno- ou indolo- da invenção. São tambémprovidenciados métodos de tratamento de distúrbiosneurodegenerativos e/ou inflamação.
BR9913190-0A 1998-08-26 1999-08-18 Modulação de proteìnas quinase de linhagemmúltipla BR9913190A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9798098P 1998-08-26 1998-08-26
PCT/US1999/018864 WO2000013015A1 (en) 1998-08-26 1999-08-18 Modulating multiple lineage kinase proteins

Publications (1)

Publication Number Publication Date
BR9913190A true BR9913190A (pt) 2001-12-11

Family

ID=22266038

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913190-0A BR9913190A (pt) 1998-08-26 1999-08-18 Modulação de proteìnas quinase de linhagemmúltipla

Country Status (25)

Country Link
EP (1) EP1105728B1 (pt)
JP (1) JP2002523780A (pt)
KR (1) KR100700028B1 (pt)
CN (3) CN1206535C (pt)
AT (1) ATE293254T1 (pt)
AU (1) AU765637B2 (pt)
BG (1) BG105360A (pt)
BR (1) BR9913190A (pt)
CA (1) CA2339539A1 (pt)
CZ (1) CZ2001701A3 (pt)
DE (1) DE69924738T2 (pt)
DK (1) DK1105728T3 (pt)
EA (2) EA006648B1 (pt)
ES (1) ES2241316T3 (pt)
HK (1) HK1037722A1 (pt)
HU (1) HUP0103079A3 (pt)
NO (1) NO20010389L (pt)
NZ (1) NZ509612A (pt)
PL (1) PL346246A1 (pt)
PT (1) PT1105728E (pt)
SK (1) SK2542001A3 (pt)
TR (2) TR200400635T2 (pt)
UA (1) UA74772C2 (pt)
WO (1) WO2000013015A1 (pt)
ZA (1) ZA200100835B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
JP2005503102A (ja) * 2000-08-11 2005-02-03 セフアロン・インコーポレーテツド 多重系統キナーゼタンパク質の調節および多重系統キナーゼタンパク質を調節する化合物のスクリーニング方法。
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2003052395A (ja) * 2001-08-09 2003-02-25 Japan Tissue Engineering:Kk 移植適正判定方法
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
EP2240783A2 (en) * 2008-02-04 2010-10-20 Galapagos N.V. Molecular targets and compounds, methods to identify the same, useful in the treatment of neurodegenerative diseases.
US20100056609A1 (en) * 2008-08-26 2010-03-04 Washington University Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
AU2015202365B2 (en) * 2008-10-22 2016-11-24 Genentech, Inc. Modulation of axon degeneration
CN104689316A (zh) 2008-10-22 2015-06-10 弗·哈夫曼-拉罗切有限公司 轴突变性的调节
CN104043126A (zh) * 2009-10-22 2014-09-17 霍夫曼-拉罗奇有限公司 轴突变性的调节
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
WO2013177367A2 (en) 2012-05-23 2013-11-28 The Johns Hopkins University Compounds and methods of use thereof for treating neurodegenerative disorders
CN109060472A (zh) * 2018-07-20 2018-12-21 上海市农业科学院 一种适于荧光染色的草菇菌褶组织切片的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions

Also Published As

Publication number Publication date
CN1206535C (zh) 2005-06-15
NO20010389L (no) 2001-04-02
TR200100589T2 (tr) 2001-07-23
WO2000013015A1 (en) 2000-03-09
NZ509612A (en) 2003-10-31
EP1105728A1 (en) 2001-06-13
AU5679399A (en) 2000-03-21
UA74772C2 (en) 2006-02-15
HUP0103079A3 (en) 2004-03-01
NO20010389D0 (no) 2001-01-23
CA2339539A1 (en) 2000-03-09
JP2002523780A (ja) 2002-07-30
CN1314999A (zh) 2001-09-26
CN1589788A (zh) 2005-03-09
DE69924738T2 (de) 2006-03-02
EA200100278A1 (ru) 2002-06-27
HUP0103079A2 (hu) 2001-12-28
HK1037722A1 (en) 2002-02-15
PT1105728E (pt) 2005-07-29
KR20010103573A (ko) 2001-11-23
DE69924738D1 (de) 2005-05-19
ES2241316T3 (es) 2005-10-16
AU765637B2 (en) 2003-09-25
EP1105728B1 (en) 2005-04-13
CN1879617A (zh) 2006-12-20
TR200400635T2 (tr) 2005-10-21
EA006648B1 (ru) 2006-02-24
WO2000013015A8 (en) 2000-05-11
CZ2001701A3 (cs) 2002-04-17
ZA200100835B (en) 2002-06-26
SK2542001A3 (en) 2002-06-04
PL346246A1 (en) 2002-01-28
BG105360A (bg) 2001-10-31
EA200500934A1 (ru) 2006-04-28
DK1105728T3 (da) 2005-08-08
ATE293254T1 (de) 2005-04-15
KR100700028B1 (ko) 2007-03-27

Similar Documents

Publication Publication Date Title
BR9913190A (pt) Modulação de proteìnas quinase de linhagemmúltipla
EA200000449A1 (ru) Модифицированные витамины к-зависимые полипептиды
AU8101698A (en) Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
TR200001312T2 (tr) Benzotiyazol protein tirozin kinaz önleyicileri.
EA200200105A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ PPARγ;
ATE230394T1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
ATE333645T1 (de) Peptide und zusammensetzungen, die die apoptose modulieren.
DE69432055D1 (de) Verwendung von einem mittel, das tyrosinphosphorylierung moduliert, zur modulation der durchlässigkeit einer physiologischen sperrschicht
BR0015416A (pt) Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos
WO2005010215A3 (en) Methods for identifying tolerance modulatory compounds and uses therefor
NZ332954A (en) Use of BPI protein products to treat humans with hemorrhage due to trauma
PT862622E (pt) Metodo de rastreio para compostos que interagem com proteina cinase rac
BR0008732A (pt) Métodos para detectar atividade de caspase derivada de membrana e seus moduladores
DE69943222D1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
AU2002248180A1 (en) Non-apoptotic forms of cell death and methods of modulation
WO1997008934A3 (en) Aryl acrylic acid derivatives useful as protein tyrosine phosphatase inhibitors
ATE302215T1 (de) Modulatoren von intrazellulären entzündungs-, zelltod- und zellüberlebenswegen, die card- und kinase-domänen enthalten
WO2002014536A3 (en) Odulating multiple lineage kinase proteins
WO1999047709A3 (en) Methods for identifying anti-cancer agents
DE60225530D1 (de) Phosphorylierte glyoxalase i und deren verwendung
DE59910697D1 (de) Verwendung von D-Galaktose zur Verhinderung von Nekrosen
ECSP982633A (es) Inhibidores de la proteina tirosina cinasa de imidazoquinozalinoa
DE69626010D1 (de) Verwendung von tropolon derivate zur hemmung des inositmono phosphatase
PT1169054E (pt) Produtos e metodos para tratar doencas relacionadas com ptp lar

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO - DE ACORDO COM OS ARTS. 8O E 10 (VIII) DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.